When Dry Eye Treatment Isn't Working: A Diagnostic Approach

November 9, 2026

A patient returns for a follow-up visit and says: "The treatment isn't working."

This is a common and clinically challenging situation. The first instinct may be to change the treatment, increase its intensity or add another product. But persistent symptoms do not necessarily mean that the treatment has failed. Sometimes the underlying mechanism has not been correctly identified. Sometimes several mechanisms are contributing simultaneously. And sometimes the patient's symptoms and objective findings do not tell the same story.

When dry-eye treatment appears ineffective, the most useful next step may therefore be to reassess the diagnosis before changing the treatment plan.

When Should We Consider That Treatment Is Not Working?

There is no single definition of treatment failure. However, symptoms alone do not necessarily demonstrate treatment failure. A more useful approach is to compare symptoms, clinical signs, objective measurements, treatment adherence and time since treatment began.

Only then can clinicians determine whether the current strategy is actually insufficient.

Step 1: Reconsider the Diagnosis

Before changing therapy, ask a fundamental question: are we treating the correct mechanism?

Dry Eye is a multifactorial disease. If the dominant mechanism has not been identified, treatment may provide limited benefit.

Patients can have similar symptoms but very different underlying mechanisms.

• Patient A Predominantly reduced aqueous tear production.
• Patient B Predominantly evaporative dry eye associated with MGD.
• Patient C Mixed aqueous and evaporative disease.
• Patient D Significant ocular-surface symptoms with relatively limited objective findings.

The treatment approach may need to be different in each case.

This is why persistent symptoms should trigger reassessment rather than automatically triggering escalation.

Step 2: Ask Whether the Treatment Has Been Used Correctly

Before concluding that a treatment has failed, adherence should be considered. Questions may include:

• Is the patient using the treatment as prescribed?
• How frequently? For how long?
• Is the technique correct?
• Is the patient using multiple products inconsistently?
• Are symptoms causing the patient to modify the treatment schedule?

Even appropriate treatment may appear ineffective if it is not being used consistently or correctly.

Step 3: Reassess the Eyelids

The eyelids are an important part of ocular-surface health. A patient who continues to experience dry-eye symptoms should be evaluated for:

• Blepharitis
• Meibomian gland dysfunction
• Lid-margin inflammation
• Abnormal gland openings
• Eyelid irregularity
• Incomplete blinking
• Other eyelid abnormalities

If the underlying problem involves the eyelids or meibomian glands, simply increasing lubrication may not address the entire mechanism.

Step 4: Evaluate Meibomian Gland Function

Meibomian gland function can provide important information in patients with persistent symptoms. A patient may continue to experience symptoms because the lipid component of the tear film remains compromised.

This is particularly relevant when evaporative dry eye is suspected.

Step 5: Look at Gland Structure

Functional assessment tells us how the glands are working. Meibography provides another perspective: what do the glands look like?

Meibography should complement rather than replace functional gland assessment.

Step 6: Reassess Tear-Film Stability

If symptoms continue despite treatment, tear-film stability should also be reconsidered.

Fluctuating Vision Is an Important Clue

One useful clinical question is: "Does your vision become clearer after blinking?"

If the answer is yes, tear-film instability may be contributing to the visual symptoms. This does not establish a diagnosis by itself, but it can provide an important clue. The tear-film is part of the eye's optical system. When it becomes unstable, visual quality can fluctuate.

Step 7: Evaluate the Ocular Surface

Persistent symptoms should also prompt reassessment of the ocular surface itself. Depending on the clinical context, clinicians may evaluate:

• Corneal staining
• Conjunctival staining
• Conjunctival redness
• Epithelial abnormalities
• Other signs of surface stress

The objective is to determine whether the ocular surface shows signs consistent with the patient's symptoms.

When Symptoms and Signs Don't Match

One of the most difficult situations is the patient who reports severe symptoms but has relatively modest clinical findings. This does not mean that the symptoms are not real. Instead, it may indicate that additional mechanisms need to be considered.

Possible contributors can include:

• Ocular-surface inflammation
• Neuropathic mechanisms
• Sensory abnormalities
• Environmental triggers
• Behavioral factors
• Coexisting ocular conditions

This is an important reason not to rely on a single diagnostic test.

Additionally, the opposite situation also occurs. A patient may show significant meibomian gland dropout, tear-film abnormalities and ocular-surface changes while reporting relatively few symptoms.

This can happen because structural changes and symptom perception do not necessarily progress at the same rate.

Step 8: pro Review Environmental Factors and Lifestyle

A patient's environment can have a major effect on ocular-surface symptoms. A treatment that works reasonably well under normal conditions may appear ineffective when environmental exposure increases.

Screen Use and Blinking

Digital-device use deserves particular attention. During prolonged screen tasks, patients may blink less frequently or incompletely. This can increase ocular-surface exposure and destabilize the tear film. A useful history therefore includes questions about:

• Daily screen time
• Continuous screen sessions
• Break frequency
• Symptoms during computer work
• Changes in blinking behavior

Contact-Lens Use

Contact lenses can contribute to ocular-surface symptoms or amplify pre-existing problems. If symptoms occur predominantly during lens wear, the diagnostic approach may need to include contact-lens-related factors.

Medications

Some medications can influence tear production, ocular-surface symptoms or blinking. A complete medication history may therefore be relevant when symptoms persist.

The objective is not to assume that medication is the cause, but to identify potentially contributing factors.

Step 9: Consider Blepharitis and Demodex

Persistent symptoms should also prompt consideration of eyelid disease. Clinical findings such as lid-margin inflammation, lash debris, cylindrical dandruff, abnormal meibomian gland openings may suggest blepharitis or clinically relevant Demodex-associated disease.

These conditions can coexist with dry eye and may need to be addressed as part of the broader diagnostic picture.

Step 10: Ask Whether the Patient Has a Mixed Mechanism

Many patients do not fit neatly into a single category.

For example:

• Aqueous deficiency
• MGD
• Eyelid inflammation
• Environmental exposure

can all contribute to the same patient's symptoms.

If treatment targets only one component, the patient may experience partial or limited improvement. This is one of the most common reasons a seemingly appropriate treatment strategy may not produce the expected result.

A Diagnostic Matrix

A useful way to think about persistent dry-eye symptoms is to divide the assessment into several levels.

Level	Key Question	Examples
Symptoms	What does the patient experience?	Dryness, burning, blur
Eyelids	Are the lids contributing?	Blepharitis, MGD
Glands	How are the glands functioning?	Expressibility, meibum
Structure	What do the glands look like?	Meibography
Tear film	Is it stable?	Break-up, evaporation
Surface	Is there ocular-surface damage?	Staining, redness
Environment	What makes symptoms worse?	Screens, air conditioning
Behavior	Could blinking contribute?	Reduced/incomplete blinking
Other factors	Is another diagnosis present?	Allergy, neuropathic pain

The goal is to connect these observations rather than interpret them independently.

Additionally, one of the challenges in assessing treatment response is knowing what the patient's starting point was. A baseline examination can help determine whether the patient has improved, remained stable or deteriorated.

Treatment Response Should Be Measured

"Feeling better" is important. But objective measurements can add another dimension. The most useful assessment often combines subjective and objective outcomes.

What If the Measurements Improve but Symptoms Don't?

This is another challenging scenario. Suppose objective tear-film parameters improve but the patient continues to report severe discomfort. The clinician should not simply conclude that the patient is "wrong." Instead, this discrepancy can be diagnostically useful.

It may indicate:

• Persistent inflammation
• Sensory abnormalities
• Neuropathic mechanisms
• Environmental triggers
• Another ocular condition
• A mismatch between the measured parameter and the patient's dominant symptom mechanism

The discrepancy itself is information.

What If Symptoms Improve but Measurements Don't?

The reverse can also occur. A patient may feel significantly better even though quantitative measurements show limited structural change. This may indicate functional improvement without major anatomical change. It is a reminder that the goal of clinical care is not necessarily to normalize every measurement. The goal is to improve the patient's ocular health and experience.

When to Think Beyond Dry Eye

Persistent symptoms despite apparently appropriate management should sometimes prompt consideration of other conditions. Depending on the presentation, clinicians may need to consider:

• Ocular allergy
• Blepharitis or Demodex-associated disease
• Corneal or conjunctival disease
• Contact-lens-related complications
• Neuropathic ocular pain
• Eyelid disorders
• Other ocular or systemic contributors

The purpose is not to make the differential diagnosis unnecessarily broad. It is to avoid assuming that every symptom represents the same mechanism.

The Role of Imaging

Imaging can be particularly useful when structural information is clinically relevant. For example, meibography may reveal significant gland dropout in a patient with persistent evaporative symptoms. This does not automatically establish causation. However, it can provide objective evidence that contributes to the overall clinical assessment.

Standardization Matters

When monitoring changes over time, measurements should ideally be obtained using consistent methods. Otherwise, technical differences may be mistaken for biological changes. The strongest diagnostic conclusions often emerge when multiple findings point in the same direction. This is the principle of diagnostic correlation.

A Patient-Centered Perspective

The goal is not to normalize a test. It is to improve the patient's ocular health and quality of life. A patient may care less about a gland-loss percentage than about being able to:

• Read comfortably
• Work at a computer
• Wear contact lenses
• Drive
• Spend time outdoors
• Maintain clear vision

Objective diagnostics should therefore support clinical decisions rather than become an end in themselves.

Conclusion

When dry-eye treatment does not produce the expected improvement, the answer is not always another treatment.

Persistent symptoms can be a signal that the underlying mechanism needs to be reassessed. The combination of clinical examination, objective measurements and longitudinal documentation can help clinicians understand why a patient remains symptomatic.

Perhaps the most important principle is simple: when treatment isn't working, don't just treat them more. Diagnose better.

A more precise understanding of the underlying mechanism can lead to a more targeted and individualized approach to ocular-surface management.

Key Takeaways

• Persistent symptoms do not automatically mean that treatment has failed.
• Before changing treatment, reassess the underlying diagnosis and mechanism.
• Dry eye is multifactorial and different mechanisms may coexist.
• Treatment adherence and correct application should be verified.
• The eyelids and meibomian glands should be evaluated in persistent cases.
• Environmental exposure, screen use and contact lenses can amplify symptoms.
• Blepharitis and Demodex-associated disease may coexist with dry eye.
• Symptoms and objective findings may not always correlate.
• Treatment response should ideally include both subjective and objective measures.
• When symptoms persist, alternative or additional diagnoses should be considered.
• The most useful approach is to identify the dominant mechanism before escalating treatment.

Frequently Asked Questions

Why isn't my dry-eye treatment working?

There can be several reasons. The underlying mechanism may not have been correctly identified, multiple mechanisms may coexist, treatment adherence may be inconsistent, or another ocular-surface condition may be contributing.

Does persistent dry eye mean I need stronger treatment?

Not necessarily. Persistent symptoms should first prompt a reassessment of the diagnosis, contributing factors and treatment response.

Can MGD cause persistent dry-eye symptoms?

Yes. Meibomian gland dysfunction can contribute to evaporative tear-film instability and may be an important factor in patients whose symptoms persist.

Why is meibography useful?

Meibography provides structural information about the meibomian glands, including gland shortening, dropout and morphological changes.

Can meibography show whether treatment is working?

It can help document structural changes over time, but structural change may occur more slowly than functional or symptomatic improvement. It should therefore be combined with other clinical measurements.

What if my symptoms are severe but the examination looks relatively normal?

This discrepancy can occur. Additional factors such as inflammation, sensory abnormalities, environmental triggers or neuropathic mechanisms may need to be considered.

What if my symptoms improve but my meibography does not?

This can represent functional improvement without significant structural recovery. Previously lost gland tissue may not rapidly return even when symptoms improve.

Can blepharitis make dry eye worse?

Yes. Eyelid inflammation and meibomian gland dysfunction can contribute to tear-film instability and ocular-surface symptoms.

Should Demodex be considered in persistent blepharitis?

When characteristic findings such as cylindrical dandruff are present, Demodex may be a relevant contributor and can be considered as part of the differential diagnosis.

How long should dry-eye treatment be tried before reassessment?

There is no single timeframe appropriate for every treatment or patient. Follow-up should depend on the treatment used, disease severity and clinical objectives.

What is the most important principle when treatment is not working?

The most useful next step may be to determine why the patient remains symptomatic rather than simply adding another treatment.